开发一种基于定量流式细胞术的检测方法以评估恶性疟原虫子孢子感染情况。
Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites.
作者信息
Kaushansky Alexis, Rezakhani Nastaran, Mann Henning, Kappe Stefan H I
机构信息
Seattle Biomedical Research Institute, Seattle, WA, United States.
出版信息
Mol Biochem Parasitol. 2012 May;183(1):100-3. doi: 10.1016/j.molbiopara.2012.01.006. Epub 2012 Feb 8.
Abstract
The human malaria parasite Plasmodium falciparum causes the most deadly parasitic disease worldwide, necessitating the development of interventions that block infection. Yet, preclinical assays to measure inhibition of infection date from the 1980s and are based on microscopy. Here, we describe the development of a simple flow cytometric assay that can be used to quantitatively assess P. falciparum sporozoite infection in vitro in low and medium throughput. We demonstrate the utility of this assay for assessing both drug inhibition of infection and measuring efficacy of antibodies in blocking parasite infection. This methodology will aid in assessing functional antibody responses to vaccination and novel drugs that prevent mosquito-to-man transmission of malaria.
摘要
人类疟原虫恶性疟原虫导致了全球最致命的寄生虫病，因此需要开发能够阻断感染的干预措施。然而，用于测量感染抑制的临床前检测方法可追溯到20世纪80年代，且基于显微镜检查。在此，我们描述了一种简单的流式细胞术检测方法的开发，该方法可用于在低通量和中通量条件下体外定量评估恶性疟原虫子孢子感染。我们证明了该检测方法在评估药物对感染的抑制作用以及测量抗体阻断寄生虫感染的效力方面的实用性。这种方法将有助于评估针对预防疟疾从蚊到人的传播的疫苗接种和新型药物的功能性抗体反应。
相似文献
1
Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites.
Mol Biochem Parasitol. 2012 May;183(1):100-3. doi: 10.1016/j.molbiopara.2012.01.006. Epub 2012 Feb 8.
2
An Opsonic Phagocytosis Assay for Plasmodium falciparum Sporozoites.
Clin Vaccine Immunol. 2017 Feb 6;24(2). doi: 10.1128/CVI.00445-16. Print 2017 Feb.
3
An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens.
Sci Rep. 2017 Dec 5;7(1):17011. doi: 10.1038/s41598-017-17274-5.
4
The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.
Infect Immun. 2017 Jan 26;85(2). doi: 10.1128/IAI.00498-16. Print 2017 Feb.
5
Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.
Malar J. 2019 May 29;18(1):186. doi: 10.1186/s12936-019-2819-6.
6
Flow Cytometry-Based Assessment of Antibody Function Against Malaria Pre-erythrocytic Infection.
Methods Mol Biol. 2015;1325:49-58. doi: 10.1007/978-1-4939-2815-6_4.
7
Quantitative Plasmodium sporozoite neutralization assay (TSNA).
J Immunol Methods. 2004 Sep;292(1-2):157-64. doi: 10.1016/j.jim.2004.06.017.
8
Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection.
Cell Microbiol. 2016 Dec;18(12):1739-1750. doi: 10.1111/cmi.12608. Epub 2016 May 27.
9
Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.
Malar J. 2009 Oct 23;8:235. doi: 10.1186/1475-2875-8-235.
10
Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens.
Front Immunol. 2020 Feb 21;11:190. doi: 10.3389/fimmu.2020.00190. eCollection 2020.
引用本文的文献
1
A genetically engineered parasite vaccine provides protection from controlled human malaria infection.
Sci Transl Med. 2022 Aug 24;14(659):eabn9709. doi: 10.1126/scitranslmed.abn9709.
2
Current status of experimental models for the study of malaria.
Parasitology. 2022 Feb 21;149(6):1-22. doi: 10.1017/S0031182021002134.
3
PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
PLoS Pathog. 2021 May 28;17(5):e1009594. doi: 10.1371/journal.ppat.1009594. eCollection 2021 May.
4
In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP).
Sci Rep. 2021 Mar 5;11(1):5318. doi: 10.1038/s41598-021-84622-x.
5
Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens.
Front Immunol. 2020 Feb 21;11:190. doi: 10.3389/fimmu.2020.00190. eCollection 2020.
6
Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection.
Clin Infect Dis. 2020 Jun 10;70(12):2544-2552. doi: 10.1093/cid/ciz740.
7
Vaccination With Sporozoites: Models and Correlates of Protection.
Front Immunol. 2019 Jun 5;10:1227. doi: 10.3389/fimmu.2019.01227. eCollection 2019.
8
Humanized Mouse Models for the Study of Human Malaria Parasite Biology, Pathogenesis, and Immunity.
Front Immunol. 2018 Apr 19;9:807. doi: 10.3389/fimmu.2018.00807. eCollection 2018.
9
A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein.
Nat Med. 2018 May;24(4):401-407. doi: 10.1038/nm.4513. Epub 2018 Mar 19.
10
Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.
J Infect Dis. 2018 Apr 23;217(10):1569-1578. doi: 10.1093/infdis/jiy080.
本文引用的文献
1
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
N Engl J Med. 2011 Nov 17;365(20):1863-75. doi: 10.1056/NEJMoa1102287. Epub 2011 Oct 18.
2
Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites.
Cell Microbiol. 2011 Aug;13(8):1250-60. doi: 10.1111/j.1462-5822.2011.01617.x. Epub 2011 Jun 24.
3
Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
PLoS One. 2011 Apr 11;6(4):e18559. doi: 10.1371/journal.pone.0018559.
4
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Lancet Infect Dis. 2011 Feb;11(2):102-9. doi: 10.1016/S1473-3099(10)70262-0. Epub 2011 Jan 13.
5
Malaria parasite pre-erythrocytic stage infection: gliding and hiding.
Cell Host Microbe. 2008 Sep 11;4(3):209-18. doi: 10.1016/j.chom.2008.08.010.
6
An efficient strategy for gene targeting and phenotypic assessment in the Plasmodium yoelii rodent malaria model.
Mol Biochem Parasitol. 2008 Apr;158(2):213-6. doi: 10.1016/j.molbiopara.2007.12.006. Epub 2007 Dec 15.
7
Glucose-6-phosphate dehydrogenase deficiency.
Lancet. 2008 Jan 5;371(9606):64-74. doi: 10.1016/S0140-6736(08)60073-2.
8
A combined transcriptome and proteome survey of malaria parasite liver stages.
Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):305-10. doi: 10.1073/pnas.0710780104. Epub 2008 Jan 2.
9
Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry.
Cell Microbiol. 2008 Jan;10(1):218-24. doi: 10.1111/j.1462-5822.2007.01032.x. Epub 2007 Aug 14.
10
The global distribution of clinical episodes of Plasmodium falciparum malaria.
Nature. 2005 Mar 10;434(7030):214-7. doi: 10.1038/nature03342.
Zotero 插件